Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sonoma Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.15.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Sonoma Pharmaceuticals. This rating has held steady since November 2019, when it changed from a Hold consensus rating.
Sonoma Pharmaceuticals, Inc. engages in developing and producing Stabilized Hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. Its products educe infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Woodstock, GA.